Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle

Penethamate Hydriodide, micronised

Last verified

Veterinary medicinal product: powder and solvent for suspension for injection. Distribution category: POM-V (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Penethamate Hydriodide, micronised.1

In short: questions and answers

Does Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle need a prescription?
Prescription only. As stated in the registration decision.1
Which animals is Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle for?
Cattle.1
What is the active substance in Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle?
Penethamate Hydriodide, micronised. ATCvet code: QJ01CE90.13
What is the withdrawal period of Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle according to the leaflet?
Cattle, meat: 7 days; Cattle, milk: 4 days.3
Dispensing
Prescription only1

POM-V: Prescription Only Medicine - Veterinarian. Supplied only on a prescription written by a veterinary surgeon who has assessed the animal.12

Supplied only on a veterinarian's prescription. As stated in the registration decision.

Animal species
Cattle1
Active substance
Penethamate Hydriodide, micronised
ATCvet code
QJ01CE903
Manufacturer
Marketing authorisation holder: Boehringer Ingelheim Animal Health UK Limited

Withdrawal period

Animal speciesProductdays
Cattlemeat73
Cattlemilk43
Summary of product characteristics

Composition

Each 5g vial contains:

Penethamate hydriodide 5 million IU

Each 10g vial contains:

Penethamate hydriodide 10 million IU

Each 15ml and 30ml vial of solvent contains:

methyl parahydroxybenzoate, as preservative 1.5mg/ml

Each ml of the reconstituted product contains 269.5 mg of penethamate hydriodide.

For the full list of excipients, see section 6.1

List of excipients (section 6.1):

Methyl parahydroxybenzoate

Water for injections

Egg lecithin

Sodium citrate anhydrous

Polysorbate 81

3

Pharmaceutical form

Powder and solvent for suspension for injection

Powder vial: White to off-white crystalline powder

Solvent vial: Clear solution

3

Pharmacological properties

ATC Vet Code : QJ01CE90 : Beta lactamase sensitive penicillins.

5.1 Pharmacodynamic properties

Its mode of action is by prevention of cell wall synthesis during bacterial cell growth and is primarily bactericidal.The in-vitro spectrum of activity is mainly within the gram-positive class of bacteria eg Staphylococcus spp, Streptococcus spp, Clostridium spp, Bacillus spp etc.

5.2 Pharmacokinetic properties

Penethamate hydriodide is a prodrug which releases benzylpenicillin quantitatively at hydrolysis. The pKa-value of penethamate hydriodide is 8.4. This means that in aqueous solution at physiological pH of 7.2, 8.2% of the drug will be present as the uncharged molecule while 91.8% will be present as the ion. In aqueous solution penethamate is hydrolysed to form benzylpenicillin and diethylaminoethanol. After intramuscular injection the prodrug itself as well as the released alcohol, diethylaminoethanol has not shown any unexpected pharmacological effects.

3

Target species

Cattle, dairy

3

Indications

Bovine mastitis caused by penicillin sensitive organisms.

3

Dosage

Reconstitution: Reconstitute the suspension using the entire contents of the 5g vial with the 15ml vial of diluent OR the 10g vial with the 30 ml vial of diluent provided.

Use only 5g vial with 15ml diluent and 10g vial with 30ml diluent to provide the correct dose.

Shake well after reconstitution.

Dosage: The daily dose is 15 mg penethamate hydriodide per kg bodyweight for 3 consecutive days. This is equivalent to 5.5 ml of the reconstituted suspension per 100 kg bodyweight.

Shake well before administration.

For intramuscular use. Do not administer intravenously.

To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid under-dosing.

3

Contraindications

Do not use in animals known to be hypersensitive to penicillin.

Do not administer by intravenous injection.

3

Adverse reactions

In very rare cases anaphylactic shock may occur, which can be fatal.

3

Warnings

Special precautions for use in animals

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to benzylpenicillin and may decrease the effectiveness of treatment with other beta-lactams due to the potential for cross-resistance.

Special Precautions to be taken by the person administering the medicinal product to animals

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

1. Do not handle this product is you know you are sensitised, or if you have been advised not to work with such preparations.

2. Handle the product with great care to avoid exposure, taking all recommended precautions.

3. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

In the event of self-injection, seek medical advice.

3

Use during pregnancy, lactation or lay

Can be used during pregnancy.

3

Interactions

Penicillins should not be administered concurrently with bacteriostatic antibiotics.

3

Overdose

Penicillins have a very wide margin of safety.

3

Special warnings

None.

3

Withdrawal period

Cattle meat and offal: 7 days

Cattle milk: 96 hours

3

Incompatibilities

None known.

3

Immediate packaging

Colourless, Type I Ph Eur glass vials, closed with butyl rubber stoppers and metal caps containing either 5 or 10 g of penethamate hydriodide and 15 or 30 ml solvent to produce a reconstituted suspension.

Pack sizes:

10g vials and 30ml solvent x 10

5g vials and 15ml solvent x 10

Not all pack sizes may be marketed

3

Storage

Do not store above 25°C.

Discard unused suspension.

Keep the container in the outer carton.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life after reconstitution according to directions: Use immediately.

3

Disposal of unused product

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

3

Additional information

Vm 08327/5056

9 DATE OF FIRST AUTHORISATION

15 March 2000

10 DATE OF REVISION OF THE TEXT

August 2025

PROHIBITION OF SALE; SUPPLY AND/OR USE

Conditions or restrictions regarding supply and use: Veterinary medicinal product subject to prescription.

Administration conditions: Administration under veterinary control or supervision.

Gavin Hall Approved: 22 August 2025

3

Registration holder

Boehringer Ingelheim Animal Health UK Limited

Ellesfield Avenue

Bracknell

Berkshire

RG12 8YS

United Kingdom

3

Regulations

Sources

  1. VMD Product Information Database: Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle, 08327/5056 UK Veterinary Medicines Directorate (OGL v3.0), checked 2026-10-04 archived copy from 2026-10-04
  2. The Veterinary Medicines Regulations 2013, Schedule 3 (categories of veterinary medicinal products) UK Government, legislation.gov.uk, checked 2026-10-04 archived copy from 2026-10-04
  3. Summary of Product Characteristics: Mamyzin 269.5mg/ml Powder and Solvent for Suspension for Injection for Cattle UK Veterinary Medicines Directorate, SPC of the marketing authorisation holder, checked 2026-10-04 archived copy from 2026-10-04

Other products with the same active substance

All products with this active substance (5)

The same active substance in other countries

These are different medicines with different authorisations. The dispensing status is the one on each product's own page, which gives its basis. The leaflet of the product in hand applies.

Spain

All products with this active substance (3)

Poland

All products with this active substance (3)